|Bid||115.53 x 500|
|Ask||123.54 x 500|
|Day's Range||122.20 - 123.73|
|52 Week Range||106.26 - 128.82|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.15%|
Of the six analysts covering Atara Biotherapeutics in January 2018, four analysts have given the stock a “buy” or a higher rating, while two analysts have given it a “hold” rating. By comparison, of the 26 analysts covering Amgen (AMGN) in January 2018, 12 analysts have given the company a “buy” or a higher rating, while 14 analysts have given it a “hold” rating. Of the 31 analysts covering Celgene (CELG) in January 2018, 17 analysts have given the stock a “buy” or a higher rating, while 13 analysts have given the stock a “hold” rating, and only one analyst has given it a “sell” rating.
How Is Accelerate Diagnostics Positioned at the Start of 2018? The net sales of Accelerate Diagnostics (AXDX) increased from $24,000 in 3Q16 to $828,000 in 3Q17. For fiscal 2017, Accelerate Diagnostics is expected to report revenues of $5 million, while peers Becton Dickinson (BDX), Bruker (BRKR), and Thermo Fisher Scientific (TMO) are expected to report revenues of $12 billion, $1.7 billion, and $20.5 billion, respectively.
In 1Q17, the Advisory Board (ABCO) reported adjusted EBITDA of ~$45 million, which was higher than its guidance of $37 million–$42 million.
A large-cap blend ETF led U.S. diversified funds in June, but small-cap names dominated the rest of the list.
Global index provider FTSE Russell just completed its annual reconstitution of key Russell indices, adjusting their mix to reflect changes in companies’ size as determined by market capitalization as well as style fit over the previous year.
Major companies are set to be pushed out of the Russell 1000 Index Friday as the Russell Investment Group evaluates what companies have a high enough market cap to be a part of the index's rank.
Francis Gannon: Chuck, we saw major reversals in the market in 2016, really the rotation from growth to value. That changed in the first quarter of this year, where growth outperformed value. Do you think the major reversal that we saw, the value ...